News: Arena Pharmaceuticals Inc (ARNA.OQ)
ARNA.OQ on NASDAQ Stock Exchange Global Select Market
6.87USD
1 Aug 2013
6.87USD
1 Aug 2013
Price Change (% chg)
$-0.08 (-1.15%)
$-0.08 (-1.15%)
Prev Close
$6.95
$6.95
Open
$7.15
$7.15
Day's High
$7.15
$7.15
Day's Low
$6.82
$6.82
Volume
1,296,797
1,296,797
Avg. Vol
1,064,672
1,064,672
52-wk High
$10.99
$10.99
52-wk Low
$6.65
$6.65
Select another date:
Thu, May 2 2013
Arena withdraws diet drug application in Europe; shares fall
- Arena Pharmaceuticals Inc withdrew an application to market its anti-obesity drug in the European Union, sending its shares down 15 percent in after-hours trading.
Select another date:
- Arena And Vivus - Why Insurance Is So Important
- Arena Pharmaceuticals Turns Q2 Profit
- Arena Pharmaceuticals' CEO Discusses Q2 2013 Results - Earnings Call Transcript
- Arena Pharma: Slow Belviq Launch But No Matter For Bel-Phen Data Coming
- Arena Pharmaceuticals, Inc. (ARNA) Management Discusses Q2 2013 Results (Webcast)
- What To Expect From Arena In Q2
Press Releases
- Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
- Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
- Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
- Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
- Technical Analysis on Arena Pharmaceuticals Inc. and ARIAD Pharmaceuticals Inc. - Biotech Momentum Slowing
- Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
- Arena Pharmaceuticals Establishes BELVIQ® (lorcaserin HCl) Marketing and Supply Agreement with Ildong Pharmaceutical for South Korea
- Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
- Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial of APD811 for Pulmonary Arterial Hypertension
- Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference

